MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-05-2024
Catalent Book Value 2011-2026 | CTLT
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.6 B | 4.61 B | 4.78 B | 4.27 B | 3.51 B | 1.68 B | 1.09 B | 724 M | 636 M | 634 M | -372 M | -410 M | -351 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.78 B | -410 M | 1.88 B |
Quarterly Book Value Catalent
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.54 B | 3.6 B | 3.61 B | 3.69 B | 3.84 B | 4.61 B | 4.7 B | 4.89 B | 4.68 B | 4.78 B | 4.63 B | 4.48 B | 4.38 B | 4.27 B | 4.07 B | 3.81 B | 3.68 B | 3.51 B | 3.51 B | 2.32 B | 2.26 B | 2.29 B | 2.29 B | 4.44 B | 4.5 B | 1.09 B | 4.53 B | 4.39 B | 3.78 B | 3.45 B | 3.45 B | 3.15 B | 3.13 B | 3.09 B | 3.09 B | 3.04 B | 3.06 B | 3.14 B | 3.15 B | 3.04 B | 2.95 B | 3.09 B | 3.09 B | - | - | -410 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.89 B | -410 M | 3.49 B |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M |  USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.11 | 4.25 % | $ 119 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 5.61 | 35.71 % | $ 362 M | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
1.71 B | $ 2.66 | 2.31 % | $ 1.39 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
52.1 M | $ 39.84 | 3.2 % | $ 1.46 B | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 0.58 | 4.82 % | $ 10.1 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.93 | -14.3 % | $ 55.3 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.67 | 5.46 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.96 | 2.96 % | $ 390 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.93 | 0.17 % | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
138 M | $ 12.19 | 2.44 % | $ 866 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
-82 M | $ 5.65 | -1.4 % | $ 2.06 B | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.41 | 3.2 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
2.94 B | $ 11.63 | 2.15 % | $ 1.61 B | USA |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 0.9 | 0.44 % | $ 21 M | USA |
 |
Sundial Growers
SNDL
|
1.13 B | $ 1.56 | 1.63 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 22.89 | 3.57 % | $ 1.06 B | USA |
 |
Veru
VERU
|
32.3 M | $ 2.6 | 3.17 % | $ 351 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
Viatris
VTRS
|
21.1 B | $ 14.81 | -0.57 % | $ 17.8 B | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 0.74 | -3.77 % | $ 3.19 M | USA |
 |
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.76 | 2.03 % | $ 143 M | USA |
 |
SCYNEXIS
SCYX
|
73 M | $ 0.76 | 0.96 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
137 M | $ 6.26 | 5.03 % | $ 256 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
3.33 B | $ 7.45 | 1.22 % | $ 4.6 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |